Patent application number | Description | Published |
20080220010 | Immunogenic Compositions for Streptococcus Agalactiae - This application relates to Group B | 09-11-2008 |
20100183674 | COMPOSITIONS COMPRISING YERSINIA PESTIS ANTIGENS - Disclosed are several | 07-22-2010 |
20100221278 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 09-02-2010 |
20100297164 | Chlamydial Antigens - The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from | 11-25-2010 |
20110070266 | IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS - The invention relates to immunogenic compositions comprising combinations of | 03-24-2011 |
20110195409 | STREPTOCOCCUS PYOGENES CLASSIFICATION - The difference Lancefield T-serotypes correlate with the sequence of the pilus backbone protein (Pbp) in | 08-11-2011 |
20120315292 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 12-13-2012 |
Patent application number | Description | Published |
20090047293 | Compositions Comprising Yersinia Pestis Antigens - Disclosed are several | 02-19-2009 |
20110052620 | HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH | 03-03-2011 |
20120066779 | HEPATITIS C RECEPTOR PROTEIN CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 03-15-2012 |
20120070456 | POLYPEPTIDE CARRIER PROTEIN - The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years. | 03-22-2012 |
20120088685 | DIAGNOSIS OF NEUROPSYCHIATRIC AND BEHAVIOURAL DISORDERS - This invention provides a method of identifying GAS infection as the cause of a neuropsychiatric or behavioural disorder in a patient, or of identifying a patient at risk of developing a neuropsychiatric or behavioural disorder caused by GAS infection. This invention also provides associated protein arrays. | 04-12-2012 |
20120093850 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective | 04-19-2012 |
20120093851 | CHLAMYDIA ANTIGENS - The invention provides | 04-19-2012 |
20120107340 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 05-03-2012 |
20130195907 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 08-01-2013 |
20130273091 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof. | 10-17-2013 |
20140093510 | CHLAMYDIA ANTIGENS - The invention provides | 04-03-2014 |
20140178425 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 06-26-2014 |
20150079124 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-19-2015 |
20150086582 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-26-2015 |
Patent application number | Description | Published |
20090025098 | Hepatitis C receptor protein CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 01-22-2009 |
20130071416 | IMMUNOGENIC PROTEINS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF STREPTOCOCCUS AGALACTIAE - The invention provides proteins and compositions for the treatment and prevention of | 03-21-2013 |
20130129740 | NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B - The invention provides proteins from group B | 05-23-2013 |
20130171238 | IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS - The invention relates to immunogenic compositions comprising combinations of | 07-04-2013 |
20130202609 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 08-08-2013 |
20140004140 | GROUP B STREPTOCOCCUS VACCINE | 01-02-2014 |
20140037671 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 02-06-2014 |
20150030625 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 01-29-2015 |